Sinocelltech Ltd.
Sinocelltech Ltd.
Explore linked clinical trials.32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10 | Healthy Participants | Not yet recruiting | Phase 1 | 2026-09-29 | NCT07847697 | |
| SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT07819188 | |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Phase 3 | 2026-08-13 | NCT07570823 | |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-13 | NCT07562022 | |
| SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors | Advanced Malignant Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-26 | NCT07665970 | |
| SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-06-23 | NCT07662395 | |
| A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-05-27 | NCT07609251 | |
| Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-18 | NCT07594028 | |
| Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-05-04 | NCT07040072 | |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 2 | 2026-04-28 | NCT07244510 | |
| A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Not yet recruiting | Phase 1 / Phase 2 | 2026-04-20 | NCT07538154 | |
| Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 3 | 2026-02-27 | NCT07437404 | |
| Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome | FRNS/SDNS; Ripertamab | Not yet recruiting | Not applicable | 2026-02-05 | NCT07388810 | |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Recruiting | Phase 3 | 2026-02-05 | NCT07388602 | |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-01-29 | NCT07297329 | |
| A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-01-23 | NCT07362459 | |
| Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD | nAMD | Recruiting | Phase 1 / Phase 2 | 2025-09-04 | NCT06672536 | |
| Phase I/II Study of SCTB39G in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2025-07-22 | NCT07077252 | |
| Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | Advanced Malignant Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-07-04 | NCT07050641 | |
| ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor | Hemophilia A With Inhibitor | Recruiting | Phase 4 | 2025-02-24 | NCT05888870 | |
| A Study of SCTB35 in Patients with Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 / Phase 2 | 2025-02-21 | NCT06841042 | |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine | Respiratory Syncytial Virus | Recruiting | Phase 1 / Phase 2 | 2025-02-13 | NCT06754605 | |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, herpes zoster, viral infectious disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-01-30 | NCT06801509 | |
| Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Not applicable | 2025-01-24 | NCT06790888 | |
| Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | Advanced Malignant Solid Tumours | Recruiting | Phase 1 / Phase 2 | 2025-01-16 | NCT06600022 |